Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here’s Why the Streak Looks Safe.

Source Motley_fool

Key Points

  • It's also seeing rising sales from liver disease and oncology products.

  • Gilead recently raised full-year guidance for revenue and EPS.

  • The cash dividend payout ratio is conservative at less than 30%.

  • 10 stocks we like better than Gilead Sciences ›

Gilead Sciences (NASDAQ:GILD) increased its dividend by 3.8% this year, the 11th consecutive year of dividend increases. Its dividend yield is above average, at 1.94%, based on the stock's current price.

The company holds a dominant position in HIV therapies, and these drugs provide dependable cash flow for the near future. Gilead is also seeing expansions into other areas, including oncology, liver, and inflammation therapies.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

There are three reasons why Gilead's dividend is a safe bet to continue to grow.

Medical researchers in a lab.

Image source: Getty Images.

Strong cash flows, low payout ratio

Over nine months, Gilead produced $10.6 billion in free cash flow, up 68% year over year, leaving its cash dividend payout ratio at just below 30%. Spending less than a third of its cash flow on its dividend leaves this pharmaceutical company with plenty of funds to buy back stock, fund research and development, and increase its dividend.

Patents protect its HIV franchise

The company's lead drug, Biktarvy, brought in $4.1 billion in the third quarter, up 10% year over year. It commands a 53% U.S. market share and holds patent exclusivity through 2036.

In the meantime, its newer HIV therapies, such as Yeztugo and Descovy, are rapidly improving sales. Descovy revenue rose 49% year over year to $1 billion in the third quarter, and Yeztugo's sales jumped 682% from the same period a year ago to $305 million.

Gilead is diversifying its revenue streams

While HIV therapies remain its primary revenue source, the company has worked hard to broaden its portfolio.

Breast cancer drug Trodelvy has become a blockbuster product, one of seven Gilead medications that bring in more than $1 billion a year. Trodelvy recently obtained European approval in combination with pembro to treat first-line PD-L1-positive metastatic triple-negative breast cancer. The therapy brought in $506 million in the third quarter, up 42% over the same period a year ago.

Gilead has seven clinical-stage antibody-drug conjugate oncology programs in the pipeline.

The company reported revenue of $203 million in the quarter for liver disease treatment Livdelzi, up 93% year over year. Gilead's pipeline includes 49 clinical programs, including more than a dozen inflammation and immunology candidates such as emvistegrast, which showed strong phase-2 response rates in ulcerative colitis.

Should you buy stock in Gilead Sciences right now?

Before you buy stock in Gilead Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
Nov 20, Fri
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
Nov 20, Fri
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
Nov 20, Fri
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
Nov 20, Fri
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
Nov 20, Fri
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote